Citations

Clear

815 citation(s) found for "Tang, Yu".

Impact of SGLT2i on Cardiovascular Outcomes Following Acute Myocardial Infarction With Heart Failure With Preserved Ejection Fraction: Propensity-matched Registry Study
Calcagno, Tess , Issa, Rochell , Canova, Tyler , Issa, Ryan, Menon, Venu , Griffin, Brian P. , Kwon, Deborah , Wang, Tom Kai Ming , Wang, Tom Kai Ming , Kaelber, David C. , Tang, Weihong

Mayo Clinic

Angiology | June 19, 2025 | Volume: 77 | Issue: 7 | Pages: 875-882

10.1177/00033197251345853 | PMID 40534435 Get It

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated benefits in heart failure with preserved ejection fraction (HFpEF), but their impact following acute myocardial infarction (AMI) is less well understood. Using the TriNetX Research Network (TriNetX) multi-center registry (2014–2022), we identified patients with heart failure with preserved ejection fraction (HFpEF)—defined as left ventricular ejection fraction (LVEF) >50% and New York Heart Association (NYHA) class II–IV—not previously treated with sodium-glucose co-transporter 2 inhibitors (SGLT2i) who experienced an acute myocardial infarction (AMI). Patients who initiated SGLT2i within 1-year post-AMI were compared with those who did not. Propensity score matching was used to balance cohorts ( n = 20,423 each; mean age 68.3 ± 11.0 years; 54.5% female) for demographics, comorbidities, and treatment variables. The primary outcome was a composite of major adverse cardiovascular events (MACE), including all-cause mortality, recurrent AMI, acute heart failure, and stroke. Secondary outcomes included cardiac arrest and major bleeding. SGLT2i use was associated with lower rates of MACE (3.7% vs 6.1%; P = .0005), all-cause mortality (0.9% vs 5.6%; P < .0001), and other adverse events at both 30 days and 1 year. In this large, propensity-matched cohort, SGLT2i use post-AMI in HFpEF patients was associated with favorable cardiovascular outcomes. Further studies are needed to confirm these associations.
83 | SINGLE CELL ANALYSIS REVEALS EXTENSIVE IMMUNE EXHAUSTION AND MEMORY‐CELL LIKE ORIGIN IN FOLLICULAR LYMPHOMA (FL) WITH INCREASED IRF4 EXPRESSION
Dasari, Surendra , Mukherjee, Pinku , Tang, Xinyi , Ansell, Stephen M. , Guzman, Emmanuel Contreras , Bhardwaj, Vaishali , Mukherjee, P., Yang, Zhi-Zhang , Pasqualucci, Laura , Shlomchik, Mark , Singh, Harinder , Mondello, Patrizia

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70093_83 Get It

199 | PEMBROLIZUMAB THERAPY INDUCES AN INFLAMMATORY RESPONSE IN LYMPHOMA PATIENTS BY RESHAPING MONOCYTES RESULTING IN HYPERPROGRESSIVE DISEASE
Tang, Xinyi , Mukherjee, Pinku , Wang, Y., Ansell, Stephen M. , Yang, Zhi-Zhang , Bhardwaj, Vaishali , Mukherjee, P., Wang, Yucai , Mondello, Patrizia , Pan‐Hammarström, Qiang

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_199 Get It

Metabolomic Evidence of Biological Overlap with Heart Failure with Preserved Ejection Fraction in a Subset of Pulmonary Arterial Hypertension
Reddy, Yogesh N.V. , Asokan, Aneesh K , Hemnes, Anna R. , Hill, Nicholas S. , Erzurum, Serpil C. , Beck, Gerald J. , Finet, J. Emanuel , Grünig, Gabriele , Jellis, Christine , Mathai, Stephen C. , Simpson, Catherine E. , Hemnes, Anna , Mathai, Stephen C , Simpson, Catherine E , Nishimura, Rick , Frantz, Robert P. , Hassoun, Paul M. , Barnard, John , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Rosenzweig, Erika B. , Tang, W H Wilson , Nair, K. Sreekumaran , Borlaug, Barry A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 13, 2025 | Volume: 211 | Issue: 9 | Pages: 1701-1713

10.1164/rccm.202501-0034oc | PMID 40504754 Get It

Abstract Rationale A subset of patients with group 1 pulmonary hypertension (PH) have superimposed left heart abnormalities with unclear metabolic implications. Objectives To compare serum/transpulmonary metabolome between group 1 PH stratified by heart failure with preserved ejection fraction (HFpEF) probability. Methods Patients with group 1 PH were stratified into low (&lt;25%) and high (⩾75%) HFpEF-ABA (age, body mass index, and atrial fibrillation) probability, with healthy control subjects and subjects with clinical HFpEF used for comparison of venous and transpulmonary metabolomics. Measurements and Main Results Group 1 PH + high HFpEF probability (n = 131) was associated with a significant increase in 207 metabolites (false discovery rate [FDR] P &lt; 0.05 and fold change &gt;1) (n = 193, t test) and a significant decrease in 231 metabolites (FDR P &lt; 0.05 and fold change &lt;1) (n = 193, t test) compared with group 1 PH + low HFpEF probability (n = 62). Group 1 PH + high HFpEF probability was associated with enhanced tryptophan metabolism with higher downstream kynurenine metabolite concentrations and lower serotonin concentrations (FDR P &lt; 0.002 for all, n = 193, t test). Linoleate (precursor to arachidonic acid and prostaglandins) and arginine and homoarginine (precursors to nitric oxide) were all lower in group 1 PH + high HFpEF probability (FDR P &lt; 0.03 for all, n = 193, t test). Metabolome changes in group 1 PH + high HFpEF probability overlapped with clinical HFpEF (n = 240) but were abnormal relative to control subjects (n = 85) (P &lt; 0.0001 for all, n = 456, t test). There was no evidence of differential transpulmonary uptake/release of most metabolites, suggesting probable nonpulmonary origin (except for serotonin, interaction P = 0.04; and kynurenine, interaction P = 0.03; n = 433, mixed model). Conclusions Patients with group 1 PH + high HFpEF probability have a unique metabolome characterized by enhanced tryptophan-kynurenine pathway breakdown, deficiency of amino acids (such as glycine and serine), lower serotonin, and decreased prostaglandin and nitric oxide precursors. Despite fulfilling clinical criteria for group 1 PH, these metabolome changes were comparable with clinical HFpEF, supporting biological overlap between these two forms of PH.
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma
Diamond, Benjamin , Poorebrahim, Mansour , Poos, Alexandra M. , Lee, Holly , Wiedmeier, Julia E. , Otteson, Gregory E., Tang, Hongwei , Fröhling, Stefan , Baertsch, Marc‐Andrea , Papadimitriou, Marios , Lemoine, Cendrine, Bergsagel, P. Leif , Kumar, Shaji , Weinhold, Niels , Bergsagel, P. Leif , Baughn, Linda, Wiedmeier-Nutor, J Erin, Durante, Michael , Otteson, Gregory, Rak, Alexey , Green, Damian J , Bergsagel, Leif, Braggio, Esteban , Kumar, Shaji K , Raab, Marc S , Maura, Francesco , Wiedmeier-Nutor, Julia E , Diamond, Benjamin T , Baughn, Linda B. , Kaddoura, Marcella , Durante, Michael , Jevremović, Dragan , Tang, Hongwei, Ziccheddu, Bachisio , Jelı́nek, Tomáš , Landgren, Ola , Neri, Paola , Braggio, Esteban , Raab, Marc S. , Fonseca, Rafaël , Bahlis, Nizar Jacques , Maura, Francesco

Mayo Clinic

Blood | June 10, 2025 | Volume: 146 | Issue: 13 | Pages: 1575-1585

10.1182/blood.2024028107 | PMID 40493883 Get It

Abstract Monoclonal antibodies targeting CD38 are a therapeutic mainstay in multiple myeloma (MM). Although they have contributed to improved outcomes, most patients still experience disease relapse, and little is known about tumor-intrinsic mechanisms of resistance to these drugs. Antigen escape has been implicated as a mechanism of tumor-cell evasion in immunotherapy. Yet, it is unknown whether MM cells can develop permanent resistance to anti-CD38 antibodies by acquiring genomic events leading to biallelic disruption of the CD38 gene locus. Here, we analyzed whole-genome and whole-exome sequencing data from patients 701 newly diagnosed MM, 67 patients at relapse with naivety to anti-CD38 antibodies, and 50 patients collected at relapse after anti-CD38 antibodies. We report a loss of CD38 in 10 of 50 patients (20%) after CD38 therapy, 3 of whom exhibited a loss of both copies. Two of these cases showed convergent evolution in which distinct subclones independently acquired similar advantageous variants. Functional studies on missense mutations involved in biallelic CD38 events revealed that 2 variants, L153H and C275Y, decreased binding affinity and antibody-dependent cellular cytotoxicity of the commercial antibodies daratumumab and isatuximab. However, a third mutation, R140G, conferred selective resistance to daratumumab, while retaining sensitivity to isatuximab. Clinically, patients with MM are often rechallenged with CD38 antibodies after disease progression and these data suggest that next-generation sequencing may play a role in subsequent treatment selection for a subset of patients.
Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma
Campian, Jian , Grossman, Stuart A. , Kask, Angela Shaulov , Kosydar, Samuel , Piotrowski, Anna F. , Tang, Justin , Chheda, Milan G. , Schullery, Dan, Desideri, Serena , Danda, Neeraja , Ferrando-Martinez, Sara , Lee, Byung Ha , Fling, Steven P. , Ye, Xiaobu , Grossman, Stuart A , Kosydar, Samuel R , Strowd, Roy E. , DiPersio, John F. , Schullery, Dan, D’Amico, Leonard

Mayo Clinic

Neuro-Oncology Advances | June 7, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf117 | PMID 40703805 Get It

Abstract Background High-grade gliomas (HGG) have a poor prognosis despite aggressive treatment. Severe, persistent lymphopenia occurring in HGG patients after concurrent chemoradiation is associated with worse survival. NT-I7, a long-acting interleukin-7 analog, has been shown to increase CD4 and CD8 counts in healthy, septic, and HIV-positive adults. This multi-institutional, NCI-funded dose-escalation trial is the first to evaluate NT-I7 safety and activity in HGG patients with severe treatment-related lymphopenia (TRL) and the effect of co-administered glucocorticoids. Methods Eligible HGG patients had CD4 counts &lt;300 cells/mm3 after 5 weeks of standard chemoradiation and were receiving either ≤0.75 or ≥4 mg/day of dexamethasone. Patients received a single intramuscular dose of NT-I7 (60 or 360 µg/kg) post-chemoradiation, followed by safety evaluation and multi-parameter, longitudinal monitoring of lymphocyte populations and immunologic function. Results NT-I7 was well tolerated in all 12 patients (median age 64; median CD4 count 161 cells/mm³) before the study closed prematurely. Absolute lymphocyte counts doubled in 83% (10/12; 95% CI: 51.6%-97.9%) of patients, and CD4 counts doubled in 42% (5/12; 95% CI: 15.2%-72.3%) of patients. Glucocorticoid use did not significantly affect CD4 or lymphocyte increases. Correlative immune profiling revealed increased Ki67 expression in CD4 (P &lt; .005) and CD8 (P &lt; .05) after one week, along with the expansion of CD4 and CD8 T-cell subsets and CD56 + natural killer cells. Conclusions NT-I7 is well tolerated and effectively increases lymphocyte and CD4 counts in severe TRL patients, regardless of glucocorticoid use, suggesting its potential to mitigate TRL and improve outcomes in HGG.
Left Heart Abnormalities in Patients With Lung Disease, OSA, and Chronic Thromboemboli at Risk for or With Known Pulmonary Hypertension
Reddy, Yogesh N.V. , Frantz, Robert P. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Rosenzweig, Erika B. , Hill, Nicholas S. , Erzurum, Serpil C. , Beck, Gerald J. , Finet, J. Emanuel , Jellis, Christine , Mathai, Stephen C. , Group, PVDOMICS Study, Hemnes, Anna , Horn, Evelyn M , Jellis, Christine L , Mehra, Reena , Tang, W H Wilson , Borlaug, Barry A , Nishimura, Rick , Rosenzweig, Erika B , Frantz, Robert P , Rischard, Franz P , Leopold, Jane A , Hassoun, Paul M , Mathai, Stephen C , Mehra, Reena , Tang, W.H. Wilson , Borlaug, Barry A. , Group, PVDOMICS Study

Mayo Clinic

Circulation: Heart Failure | May 29, 2025 | Volume: 18 | Issue: 8 | Pages: No page available

10.1161/circheartfailure.125.012912 | PMID 40438933 Get It

BACKGROUND: Patients with lung disease, sleep apnea, and chronic thromboemboli can develop pulmonary hypertension, currently classified as group 3 or 4. Many of these patients also have risk factors for heart failure with preserved ejection fraction (HFpEF), but the optimal approach to identify the disease overlap remains unclear. METHODS: Pretest probability for HFpEF was determined using the HFpEF-ABA (age, body mass index, atrial fibrillation) algorithm among adjudicated group 3 or 4 patients at risk for pulmonary hypertension in the PVDOMICS study (Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics). Patients were stratified by current resting right heart catheterization criteria, and in a separate analysis, stratified only by HFpEF-ABA probability into low (<25%), intermediate, and high (≥75%) HFpEF probability groups. RESULTS: Among 598 patients with group 3 disease, 27% (n=161) had elevated pulmonary capillary wedge pressure (PCWP) with postcapillary pulmonary hypertension even at rest, which was associated with the highest exercise PCWP. However, regardless of this resting PCWP-based classification, a larger subset had intermediate-to-high HFpEF-ABA probabilities (32% [n=197] high and 57% [n=358] intermediate HFpEF probability). High HFpEF probability in group 3 disease was associated with higher resting and dynamic PCWP response to NO, fluid, and exercise ( P <0.0001 for all). These changes were comparable with more traditionally defined HFpEF without pulmonary vascular disease (n=61) but less severe than those with combined precapillary and postcapillary pulmonary hypertension HFpEF (n=31; interaction P =0.006). Increasing HFpEF probability in group 3 disease was associated with worse left heart remodeling, quality of life, 6-minute walk distance, and peak VO 2 ( P <0.0001 for all). Findings were replicated in group 4 disease (n=102). CONCLUSIONS: Quantifying pretest probability for HFpEF in patients with sleep apnea, lung disease, or chronic thromboemboli identifies a progressive gradient for dynamic PCWP abnormalities with worse functional status and quality of life. These subclinical left heart abnormalities are not universally detectable by resting right heart catheterization alone and call for further study of whether strategies to prevent or treat HFpEF might improve functional status in these patients with high risk of occult HFpEF.
Comparing BRCA1/2 copy number loss assessment in circulating tumor DNA to tissue in advanced solid cancers.
Yadav, Sumeet Kumar, Giridhar, Sonya, Haddad, Tufia C. , Tang, Xiaojia , Giridhar, Sonya, Yadav, Siddhartha , Goetz, Matthew P. , Couch, Fergus J. , Kalari, Krishna R. , Giridhar, Karthik V.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e14545 Get It

e14545 Background: Next generation sequencing (NGS) identifies genomic alterations in DNA obtained from tissue biopsies and/or blood [circulating tumor (ct)DNA]. We anticipate a lower rate of copy number loss (CNL) in ctDNA compared to tissue, as lower ctDNA tumor fraction may limit the ability to detect a deletion. However, we observed several instances of a CNL in ctDNA that was not identified in a tissue specimen, prompting this systematic evaluation of an institutional dataset. We focused on BRCA1/2 pathogenic variants (PVs) given their therapeutic implications and coverage across testing platforms. Methods: Using an IRB-approved protocol, we evaluated an institutional repository of NGS results performed across the Mayo Clinic Enterprise. We focused on patients (pts) who had both tissue and blood NGS testing performed. We further narrowed this cohort to those with a BRCA1/2 PVs, somatic and/or germline, as determined by testing performed at Guardant Health, Tempus, or Foundation Medicine. We abstracted information about each variant, including type of alteration classification and functional impact. Demographic information, cancer characteristics, and germline testing information was collected. Fisher’s exact test was used to compare alteration frequencies in ctDNA vs tissue using GraphPad Prism v 10.1. Results: From Dec 2015-Sept 2024, we identified 158 unique pts with BRCA1/2 PV who had NGS results for both tissue and ctDNA. The median age at first reporting BRCA1/2 variant was 67 years (range: 29-98 years). 48% of pts were female, and the most common cancer type sites were lung (23%), colorectal (20%), and pancreaticobiliary (20%). We identified 198 unique pathogenic genomic alterations; 71 in BRCA1 & 127 in BRCA2 . Most common alteration was an SNV or indel (127/198), followed by CNL (n = 63), splice site variants (n = 5), fusions (n = 2), and rearrangements (n = 1). Of the 126 SNV or indels, 50 (39.7%) were identified in both ctDNA and tissue, 40 (31.7%) were detected in blood only, 36 (28.6%) identified only in tissue (p < 0.0001). Amongst the 63 CNL, only 3 (4.8%) were identified in both ctDNA and tissue; 41(65.1%) were only identified in ctDNA, and 19 (30.2%) in tissue only (p < 0.0001). In the 19 tissue-only CNL tests, 12/19 noted one or more additional pathogenic SNV/Indel in BRCA1/2. In the 41 ctDNA-only CNL tests, 1/41 noted one or more additional pathogenic SNV/Indel in BRCA 1/2 . Germline testing was available in 41/63 pts with copy number loss. 3/41 deletions were identified in germline (2 in ctDNA, 1 in tissue). Conclusions: We observed a low degree of concordance in CNL between tissue and ctDNA for BRCA1/2 . CNL detection in ctDNA that could not be confirmed in germline or with a second alteration warrants further attention. In particular, clinicians should be cautioned when interpreting ctDNA reports noting BRCA1/2 CNL without clarity if this represents biallelic loss or a synchronous loss of function.
Extracellular Matrix Alterations in Chronic Ischemic Cardiomyopathy Revealed by Quantitative Proteomics
Buck, Kevin M. , Gregorich, Zachery R. , Aballo, Timothy J. , Gao, Zhan , Price, Scott J., Aballo, Timothy J , Rogers, Holden T. , Mann, Morgan , Chapman, Emily A. , Perciaccante, Andrew J. , Lei, Ienglam , Tang, Paul C. , Ge, Ying Ping

Mayo Clinic

No container title available | May 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.23.655833 | PMID 40501991 Get It

Abstract Ischemic cardiomyopathy (ICM) is a leading cause of heart failure characterized by extensive remodeling of the cardiac extracellular matrix (ECM). While initially adaptive, ECM deposition following ischemic injury eventually turns maladaptive, promoting adverse cardiac remodeling. The strong link between the extent of fibrosis and adverse clinical outcomes has led to growing interest in ECM targeted therapies to prevent or reverse maladaptive cardiac remodeling in ICM; yet, the precise composition of the ECM in ICM remains poorly defined. In this study, we employed a sequential protein extraction enabled by the photocleavable surfactant Azo to enrich ECM proteins from left ventricular tissues of patients with end-stage ICM (n=16) and nonfailing donor hearts (n=16). High-resolution mass spectrometry-based quantitative proteomics identified and quantified over 6,000 unique protein groups, including 315 ECM proteins. We discovered significant upregulation of key ECM components, particularly glycoproteins, proteoglycans, collagens, and ECM regulators. Notably, LOXL1, FBLN1, and VCAN were among the most differentially expressed. Functional enrichment analyses revealed enhanced TGFβ signaling, integrin-mediated adhesion, and complement activation in ICM tissues, suggesting a feedback loop driving continued ECM deposition in the end-stage failing heart. Together, our findings provide a comprehensive proteomic landscape of ECM alterations in the end-stage ICM myocardium and identify promising molecular targets for therapeutic intervention.